Status: Not yet recruiting
A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With Acromegaly
he purpose of this study is to evaluate the efficacy and safety of SYHX2008 injection in in patients with acromegaly.
Participants needed: 154
Trial details
Phase: Phase 3Age: 18-80Biological sex: AllType: InterventionalSponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Updated: Jun 3, 2026
Eligibility criteria
Male or female participants aged 18 to 80 years (including boundary values) [+1]
Have received pituitary radiotherapy within the 5 years prior to screening [+5]